Nektar Therapeutics
NKTR
Delayed Nasdaq - 04/23 10:00:00 pm
85.45USD
-0.88%
Prev.86.2100
Open86.8000
High86.8800
Low82.1100
Volume2 860 138
Last news
Financials
Sales 2018 540 M
EBIT 2018 57,2 M
R. net 2018 27,0 M
Debt 2018 -
Rend. 2018 -
P/E ratio 2018 85 450,00
P/E ratio 2019
Capi. / Sales 2018 25,7x
Capi. / Sales 2019 43,0x
Capitalization 13 873 M
Company
Nektar Therapeutics is a clinical-stage biopharmaceutical company, which engages in developing drug candidates that utilize its PEGylation and polymer conjugate technology platforms.Its products contain drug candidates of therapeutic areas, including oncology, pain, anti-infectives, anti-viral, and...
Sector :
Biotechnology & Medical Research - NEC
Calendar :
2018-04-28 Presentation
Trading Rating :
Investor Rating :
Technical analysis trends
Short TermMid-TermLong Term
TrendBearishBullishBullish
Resistance93,9108108
Spread/Res.-9,0%-21%-21%
Spread/Supp.0,62%49%99%
Support84,957,443,0